521 related articles for article (PubMed ID: 18650512)
21. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
22. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Murray JM; Emery S; Kelleher AD; Law M; Chen J; Hazuda DJ; Nguyen BY; Teppler H; Cooper DA
AIDS; 2007 Nov; 21(17):2315-21. PubMed ID: 18090280
[TBL] [Abstract][Full Text] [Related]
23. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.
Mangiafico L; Perja M; Fusco F; Riva S; Mago D; Gringeri A
Haemophilia; 2012 Jan; 18(1):108-11. PubMed ID: 21762404
[TBL] [Abstract][Full Text] [Related]
24. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
[TBL] [Abstract][Full Text] [Related]
25. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
[TBL] [Abstract][Full Text] [Related]
26. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H;
J Acquir Immune Defic Syndr; 2007 Oct; 46(2):125-33. PubMed ID: 17721395
[TBL] [Abstract][Full Text] [Related]
27. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
Gulick RM; Su Z; Flexner C; Hughes MD; Skolnik PR; Wilkin TJ; Gross R; Krambrink A; Coakley E; Greaves WL; Zolopa A; Reichman R; Godfrey C; Hirsch M; Kuritzkes DR;
J Infect Dis; 2007 Jul; 196(2):304-12. PubMed ID: 17570119
[TBL] [Abstract][Full Text] [Related]
29. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
[TBL] [Abstract][Full Text] [Related]
30. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
31. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
32. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Markowitz M; Morales-Ramirez JO; Nguyen BY; Kovacs CM; Steigbigel RT; Cooper DA; Liporace R; Schwartz R; Isaacs R; Gilde LR; Wenning L; Zhao J; Teppler H
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):509-15. PubMed ID: 17133211
[TBL] [Abstract][Full Text] [Related]
33. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
Kravchenko AV
Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Lennox JL; DeJesus E; Lazzarin A; Pollard RB; Madruga JV; Berger DS; Zhao J; Xu X; Williams-Diaz A; Rodgers AJ; Barnard RJ; Miller MD; DiNubile MJ; Nguyen BY; Leavitt R; Sklar P;
Lancet; 2009 Sep; 374(9692):796-806. PubMed ID: 19647866
[TBL] [Abstract][Full Text] [Related]
35. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
36. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
Eron JJ; Rockstroh JK; Reynes J; Andrade-Villanueva J; Ramalho-Madruga JV; Bekker LG; Young B; Katlama C; Gatell-Artigas JM; Arribas JR; Nelson M; Campbell H; Zhao J; Rodgers AJ; Rizk ML; Wenning L; Miller MD; Hazuda D; DiNubile MJ; Leavitt R; Isaacs R; Robertson MN; Sklar P; Nguyen BY;
Lancet Infect Dis; 2011 Dec; 11(12):907-15. PubMed ID: 21933752
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.
Eron JJ; Cooper DA; Steigbigel RT; Clotet B; Gatell JM; Kumar PN; Rockstroh JK; Schechter M; Markowitz M; Yeni P; Loutfy MR; Lazzarin A; Lennox JL; Strohmaier KM; Wan H; Barnard RJ; Nguyen BY; Teppler H;
Lancet Infect Dis; 2013 Jul; 13(7):587-96. PubMed ID: 23664333
[TBL] [Abstract][Full Text] [Related]
38. Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of raltegravir in HIV/AIDS.
Chaudhary MA; Elbasha EH; Kumar RN; Nathanson EC
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):627-39. PubMed ID: 22098278
[TBL] [Abstract][Full Text] [Related]
40. The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients.
Hill AM; Cho M; Mrus JM
AIDS Rev; 2011; 13(1):41-8. PubMed ID: 21412388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
